Am J Transplant, Volume 19, Suppl 3 Archives - Page 60 of 214 - ATC Abstracts

2019 American Transplant Congress
Evaluation of Envarsus XR in African American Kidney Transplant Recipients
L. R. Lineberger¹, E. Hollinger², N. Kenyon¹, M. Brokohf¹, N. Alvey¹
¹Pharmacy, Rush University Medical Center, Chicago, IL, ²Rush University Medical Center, Chicago, IL
*Purpose: This study is being conducted to evaluate the clinical impact of the utilization of tacrolimus LCP (TAC-LCP) compared to tacrolimus immediate release (TAC-IR) in…
2019 American Transplant Congress
Outcomes in Kidney Transplant Recipients after Conversion from Tacrolimus to Belatacept-Based Regimens
H. Underwood, N. Lange, J. Hedvat, C. Brennan, D. Tsapepas, K. King, S. Husain, D. Salerno, S. Patel, S. Mohan, R. Crew
Columbia University Irving Medical Center, New York, NY
*Purpose: Immunosuppressive strategies for belatacept are variable and associated outcomes have not been well described. We examined outcomes among kidney transplant (KT) recipients converted from…
2019 American Transplant Congress
Long-Term Kidney Graft Evolution in Simultaneous Liver-Kidney Transplants with Immunological Risk
G. J. Piñeiro¹, E. Montagud¹, J. Ugalde¹, R. Gelpi¹, V. Torregrosa¹, J. Rovira², J. Colmenero³, F. Diekmann¹, N. Esforzado¹
¹Nephrology and Kidney Transplantation, Hospital Clínic of Barcelona, Barcelona, Spain, ²Nephrology and Kidney Transplantation, Laboratori Experimental de Nefrologia i Trasplantament, IDIBAPS, Barcelona, Spain, ³Liver Transplant Unit, Hospital Clínic of Barcelona, Barcelona, Spain
*Purpose: There is disagreement about the real impact of anti-HLA sensitization on patient and kidney graft survival in simultaneous liver-kidney transplant (SLKT).*Methods: We reviewed the…
2019 American Transplant Congress
Outcomes of Inguinal and Incisional Hernias in Patients Undergoing Liver Transplant
H. Aziz, V. Tristan, Y. Genyk, K. Etesami
Transplant Surgery, USC, Los Angeles, CA
*Purpose: To evaluate outcomes of patients with inguinal and incisional hernias at the time of liver transplant.*Methods: We performed a retrospective analysis of our prospectively…
2019 American Transplant Congress
Liver Transplantation for Acute Liver Failure: A 16 Year Experience with 214 Patients in the Post-MELD Era
R. McMillan, T. Ito, A. Aziz, A. Amin, A. Murray, J. DiNorcia III, V. G. Agopian, H. Yersiz, D. G. Farmer, R. W. Busuttil, F. M. Kaldas
Department of Surgery, The Dumont-UCLA Transplant Center, Los Angeles, CA
*Purpose: Liver transplantation (LT) remains the gold standard treatment for acute liver failure (ALF). Our center has previously reported outcomes in the pre-Model for End…
2019 American Transplant Congress
Preventing Donor Derived Cryptococcal Infections: Should We Screen Potential Organ Donors with a Serum Cryptococcal Antigen? A Cost Analysis
C. Santos¹, E. Ritz¹, Y. Rhee¹, I. George², J. Pulvirenti³, N. Moore¹, E. Hollinger¹, L. Proia¹
¹Rush University Medical Center, Chicago, IL, ²Washington University, St. Louis, MO, ³Mercy Hospital, Rockford, IL
*Purpose: Donor-derived cryptococcosis is a rare but deadly infection. Serum cryptococcal antigen testing is a sensitive, specific and inexpensive modality that can be used to…
2019 American Transplant Congress
Phylogenetic Analysis of the Epstein Barr Virus Nuclear Antigen-1 and Associated Correlates among Canadian Transplant Patients
M. Abdulnoor¹, S. Isabel¹, T. Paton¹, N. Khodai-Booran¹, T. Schechter¹, P. Birk², T. Blydt-Hansen³, B. Foster⁴, S. Mital¹, V. Phan⁵, S. Urschel⁶, G. Casallo¹, T. Papaz¹, L. Hamiwka⁷, S. Min¹, U. Allen¹
¹University of Toronto, Toronto, ON, Canada, ²University of Manitoba, Winnipeg, MB, Canada, ³University of British Columbia, Vancouver, BC, Canada, ⁴McGill University, Montreal, QC, Canada, ⁵University of Montreal, Montreal, QC, Canada, ⁶University of Alberta, Edmonton, AB, Canada, ⁷University of Calgary, Calgary, AB, Canada
*Purpose: The effect of the genetic diversity of the Epstein-Barr virus (EBV) on clinical outcomes in the transplant setting is important to study. We examined…
2019 American Transplant Congress
Infective Complications after Renal Transplantation – A Single Centre Experience Comparing Alemtuzumab to Basiliximab Induction
R. Czajka, M. Welberry Smith, M. Gittus, E. Lindley, M. Vernon
Renal Medicine, St James' University Hospital, Leeds, United Kingdom
*Purpose: Our centre predominantly uses alemtuzumab as induction immunosuppression for renal transplantation. We examined infective complications after renal transplantation, comparing different induction, and maintenance, immunosuppression…
2019 American Transplant Congress
Phenotype and Course of Renal Tubular Cell Death during Cold Ischemia versus Cold Ischemia Followed by Transplant
S. Jain¹, R. Plenter², T. Nydam², A. Jani¹
¹Renal Division, University of Colorado, Aurora, CO, ²Transplant Microsurgery Program, University of Colorado, Aurora, CO
*Purpose: Treatments of Delayed graft function (DGF) are lacking. Prolonged cold ischemia (CI) is a risk factor for DGF but the pathways by which CI…
2019 American Transplant Congress
Histone Deacetylase-8 (HDAC8) Inhibition is Protective in a Murine Model of Renal Ischemia Reperfusion Injury (IRI)
P. T. Hernandez¹, S. J. Concors¹, D. D. Aufhauser¹, L. Krumeich¹, Z. Wang¹, G. Ge¹, A. Beeler², M. Levine¹, W. Hancock³
¹Hospital of the University of Pennsylvania, Philadelphia, PA, ²Chemistry, Boston University, Boston, MA, ³Children's Hospital of Philadelphia, Philadelphia, PA
*Purpose: IRI is a major source of morbidity after renal transplantation, contributing to poor transplant outcomes and decreased graft survival. Histone deacetylases (HDACs) are enzymes…